The analysis revealed downregulation of promoter methylation of TTYH3 in BLCA, irrespective of clinicopathological characteristics, such as individual cancer stage, race, sex, age, weight, smoking status, nodal metastasis status, and histological subtype (Figure A1). Here, TTYH3 is linked to bladder transitional cell carcinoma.